CORONA Remedies Limited (NSE:CORONA)
India · Delayed Price · Currency is INR 1,750.60
+18.90 (1.09%)
At close: Jun 16, 2026
CORONA Remedies Stock Forecast
Stock Price Forecast
According to 3 analysts polled by S&P Global, CORONA Remedies stock has a consensus rating of "Strong Buy" and an average price target of ₹1,861. The average 1-year stock price forecast is 6.29% higher than the current stock price, while the lowest is ₹1,685 (-3.75%) and the highest is ₹2,047 (+16.93%).
Price Target: ₹1,861 (+6.29%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CORONA Remedies stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Apr '26 | May '26 |
|---|---|---|---|---|
| Strong Buy | 1 | 1 | 2 | 2 |
| Buy | 0 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Total | 1 | 2 | 3 | 3 |
Financial Forecast
Revenue This Year
16.51B
from 14.03B
Increased by 17.64%
Revenue Next Year
18.93B
from 16.51B
Increased by 14.70%
EPS This Year
41.61
from 32.67
Increased by 27.36%
EPS Next Year
53.13
from 41.61
Increased by 27.68%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.
Revenue Forecast
| Revenue | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 16.6B | ||
| Avg | 16.5B | ||
| Low | 16.4B |
Revenue Growth
| Revenue Growth | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 18.4% | ||
| Avg | 17.6% | ||
| Low | 16.9% |
EPS Forecast
| EPS | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 42.00 | ||
| Avg | 41.61 | ||
| Low | 41.23 |
EPS Growth
| EPS Growth | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 28.5% | ||
| Avg | 27.4% | ||
| Low | 26.2% |